Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

Rhea-AI Summary

Bio-Path Holdings, Inc. (NASDAQ: BPTH) will host a live conference call and audio webcast on March 31, 2023, at 8:30 a.m. ET to discuss its financial results for Q4 and the full year ending December 31, 2022. The company specializes in developing targeted nucleic acid cancer drugs using its proprietary DNAbilize^® technology. Bio-Path's lead candidate, prexigebersen, is in a Phase 2 study for blood cancers, while another candidate, BP1002, is being evaluated for various cancers. The call will also include a business overview, and access details are provided for both domestic and international participants.

Positive

• Bio-Path's lead product prexigebersen is in a Phase 2 study for blood cancers.
• BP1001-A has FDA clearance, with Phase 1 studies in solid tumors expected to commence.
• The company is advancing its pipeline of RNAi nanoparticle drugs with significant therapeutic potential.

Negative

• None.

HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com  

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings report financial results for Q4 and full year 2022?

Bio-Path Holdings will report its financial results on March 31, 2023.

What is the focus of Bio-Path Holdings' product pipeline?

Bio-Path Holdings focuses on developing targeted nucleic acid cancer drugs using its DNAbilize^® technology.

What is prexigebersen and its current status?

Prexigebersen is a lead product candidate targeting blood cancers and is currently in a Phase 2 study.

How can investors access the conference call on March 31?

Investors can access the conference call by calling (833) 630-1956 domestically or (412) 317-1837 internationally.